Prothena Corporation plc (PRTA)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 3:15 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow PRTA in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on PRTA and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
PRTA at a glance
Key statistics
$436.36M
Market capitalization
- Previous close
- $8.50
- Open
- $8.67
- Day range
- $8.06 – $8.67
- Volume
- 275.6K
- Average volume (30 sessions)
- 544.6K
- Shares outstanding
- 52.35M
- Earnings per share
- $(0.86)
- Price / book
- 1.5
- Price / sales
- 8.0
- Beta (1 year, vs SPY)
- 0.96
Where the price sits in its year
52-week range
8% of the range
- Below the 52-week high
- -31.6%
- Above the 52-week low
- +4.5%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $8.46+0.4%
- 50-day average
- $8.85-3.9%
- 200-day average
- $9.26-8.2%
Between the conventional 30 and 70 bands.
+1.7%
1 week
-0.1%
1 month
+0.7%
3 months
-11.0%
Year to date
-14.3%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with PRTA
PRTA on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on PRTA.
See the plans →
Every planScreen names like PRTA
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on PRTA
Put PRTA on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on PRTA
See whether there is an open premium alert on PRTA, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
PRTA headlines
- Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Benzinga · Dec 19, 2024
- Demystifying Prothena Corp: Insights From 8 Analyst Reviews
Benzinga · Mar 13, 2024
- Decoding 6 Analyst Evaluations For Prothena Corp
Benzinga · Feb 16, 2024
- Demystifying Prothena Corp: Insights From 5 Analyst Reviews
Benzinga · Jan 9, 2024
- 4 Analysts Have This to Say About Prothena Corp
Benzinga · Dec 18, 2023
- Expert Ratings for Prothena Corp
Benzinga · Oct 23, 2023
SEC Form 4, most recent first
Insider filings
SCULLY WILLIAM P
+10.0K
10% owner · Open-market purchase
$84.57K · Oct 14, 2026
SCULLY WILLIAM P
+100.0K
10% owner · Open-market purchase
$835.48K · Oct 13, 2026
SCULLY WILLIAM P
+90.0K
10% owner · Open-market purchase
$770.90K · Oct 8, 2026
SCULLY WILLIAM P
+125.0K
10% owner · Open-market purchase
$1.05M · Oct 7, 2026
SCULLY WILLIAM P
+100.0K
10% owner · Open-market purchase
$857.24K · Oct 2, 2026
SCULLY WILLIAM P
+162.0K
10% owner · Open-market purchase
$1.41M · Sep 29, 2026
SCULLY WILLIAM P
+103.5K
10% owner · Open-market purchase
$889.87K · Sep 28, 2026
SCULLY WILLIAM P
+100.0K
10% owner · Open-market purchase
$843.46K · Sep 18, 2026
About Prothena Corporation plc
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Dublin 2, L2
- Employees
- 67
- Listed since
- Dec 18, 2012
- Website
- prothena.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.